Matches in Wikidata for { <http://www.wikidata.org/entity/Q94146420> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- Q94146420 description "article scientifique publié en 2018" @default.
- Q94146420 description "wetenschappelijk artikel" @default.
- Q94146420 description "наукова стаття" @default.
- Q94146420 name "ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)" @default.
- Q94146420 name "ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)" @default.
- Q94146420 type Item @default.
- Q94146420 label "ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)" @default.
- Q94146420 label "ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)" @default.
- Q94146420 prefLabel "ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)" @default.
- Q94146420 prefLabel "ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)" @default.
- Q94146420 P1433 Q94146420-6B37BE53-3CDE-4B3E-951E-17493F58420A @default.
- Q94146420 P1476 Q94146420-FCF70D4F-0D7A-4D05-AAEC-017DDE7E2411 @default.
- Q94146420 P2093 Q94146420-059B0134-3EF5-4C62-B5AB-19B351DA20BF @default.
- Q94146420 P2093 Q94146420-24DC0A66-E701-4C6C-A65A-7DF4B1BD61FD @default.
- Q94146420 P2093 Q94146420-3A23A6D8-AABB-4AE0-AF3F-7E7E8C83CEFA @default.
- Q94146420 P2093 Q94146420-4F4818FF-1F93-48EC-B6A7-7DE7969E42A1 @default.
- Q94146420 P2093 Q94146420-6067EA02-3AAF-4A79-8895-DF3DC41EE8E4 @default.
- Q94146420 P2093 Q94146420-764D1552-DAA8-4C24-8350-9D1CBC140EF0 @default.
- Q94146420 P2093 Q94146420-7CDFB657-C313-49A4-A3E0-2E462B4F91F1 @default.
- Q94146420 P2093 Q94146420-95651FCE-AFF8-48A4-A90D-4AD762823F9B @default.
- Q94146420 P2093 Q94146420-A6AE5105-1D1E-4155-8B78-CAF64F0E7067 @default.
- Q94146420 P2093 Q94146420-B750FDB6-F030-40C3-A800-00E22A49BBC6 @default.
- Q94146420 P2093 Q94146420-C76D52E7-708F-44F5-854D-9A1E22A9291B @default.
- Q94146420 P2093 Q94146420-C88DA0BB-B725-4822-8547-8A3A14D9E4A3 @default.
- Q94146420 P2093 Q94146420-D009F8A0-97B3-4F5D-97A6-CF493EE9A7E2 @default.
- Q94146420 P2093 Q94146420-FB1AD685-2628-46A6-9FF2-A8CA0E7A8FCA @default.
- Q94146420 P304 Q94146420-9F209E59-ED12-40FC-8238-640207203EC0 @default.
- Q94146420 P31 Q94146420-D88080ED-FC28-4FAA-BF94-991D753616CF @default.
- Q94146420 P356 Q94146420-EEEFBB56-3496-4379-BD89-BBF4EC260BD2 @default.
- Q94146420 P433 Q94146420-16EF516C-68B1-44EF-81F2-84A514733E20 @default.
- Q94146420 P478 Q94146420-9635FE14-6070-42DA-B645-0E75072D01DD @default.
- Q94146420 P50 Q94146420-BD2D76B1-4F06-43CB-B301-5D5878D37251 @default.
- Q94146420 P50 Q94146420-CC6FEF33-A35B-4755-A8B8-FBAFEB844719 @default.
- Q94146420 P577 Q94146420-B1B35BB7-1C28-4411-94DA-6DC8894B132C @default.
- Q94146420 P921 Q94146420-4D476789-F597-4CC2-9010-07A61E3E1844 @default.
- Q94146420 P921 Q94146420-620BC183-A901-4056-AB8D-A2C90C65DBF9 @default.
- Q94146420 P932 Q94146420-FF0E3422-7571-48E0-8FA2-C59675A5F027 @default.
- Q94146420 P356 NOY148.063 @default.
- Q94146420 P1433 Q15724471 @default.
- Q94146420 P1476 "ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)" @default.
- Q94146420 P2093 "Andrea Pirzkall" @default.
- Q94146420 P2093 "Bing Du" @default.
- Q94146420 P2093 "David Schiff" @default.
- Q94146420 P2093 "James Battiste" @default.
- Q94146420 P2093 "Jian Campian" @default.
- Q94146420 P2093 "Katie Wood" @default.
- Q94146420 P2093 "Kent Shih" @default.
- Q94146420 P2093 "Lyndon Kim" @default.
- Q94146420 P2093 "Martin van den Bent" @default.
- Q94146420 P2093 "Rachel Wei" @default.
- Q94146420 P2093 "Song Mu" @default.
- Q94146420 P2093 "Tobias Walbert" @default.
- Q94146420 P2093 "Vanitha Ramakrishnan" @default.
- Q94146420 P2093 "Vinay Puduvalli" @default.
- Q94146420 P304 "vi17-vi18" @default.
- Q94146420 P31 Q13442814 @default.
- Q94146420 P356 "10.1093/NEUONC/NOY148.063" @default.
- Q94146420 P433 "Suppl 6" @default.
- Q94146420 P478 "20" @default.
- Q94146420 P50 Q105531697 @default.
- Q94146420 P50 Q47159504 @default.
- Q94146420 P577 "2018-11-05T00:00:00Z" @default.
- Q94146420 P921 Q282142 @default.
- Q94146420 P921 Q425088 @default.
- Q94146420 P932 "6216180" @default.